Artificial Intelligence for Evidence Synthesis of Emerging Biologics to Improve Skeletal Health in Osteogenesis Imperfecta: Systematic Review and Meta-Analysis

1

Osteogenesis imperfecta (OI) is a rare genetic disorder with an incidence of 1 in 15,000 to 20,000 live births, causing bone fragility and lifelong disability.
2

Current therapies for OI, primarily bisphosphonates, focus on symptomatic relief but show limited efficacy in adults and severe phenotypes.
3

Emerging biologics like denosumab and romosozumab target specific molecular pathways in bone remodeling, offering potential advantages over bisphosphonates.
4

A systematic review and meta-analysis of biologics for OI was conducted to evaluate their efficacy and safety, utilizing an LLM-assisted workflow.
5

The review process faced challenges due to heterogeneous study designs and inconsistent outcomes, highlighting the need for improved methodologies.

Journal Of Medical Internet Research (Jmir)

by Chengfei Li, Zonglin Dai, Wing Chung Tang, Zesen Gao, Vivien Kin Yi Chan, Mariana Ramirez-Posada, Jiyeong Kim, Eleni Linos, CL Cheung, Ian Chi Kei Wong, Dong Dong, Michael To, Dawn Craig, Xue Li
July 10, 2026

1